ClinicalTrials.Veeva

Menu

Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma

P

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Unknown

Conditions

Melanoma Cancer

Treatments

Behavioral: Melanoma scale questionnair

Study type

Observational

Funder types

Other

Identifiers

NCT02879474
AORC 2009
RC13_0082 (Other Identifier)

Details and patient eligibility

About

State of the question Over the past decade, the incidence of melanoma (MM) has steadily increased in France and in most developed countries. This increased incidence was concerned mainly MM thin while the incidence of MM thick that represent the true "killers", and mortality from MM remained stable or increased slightly over the same period. These epidemiological data and observations from everyday medical practice dermatologists suggest the existence of different growth patterns within MM. Indeed, some MM progressing slowly sometimes for decades before diagnosis but are thin at the time of resection. Conversely, others MM grow very quickly, resulting in thick tumors despite a diagnosis and resection sometimes very early. These fast growing MM (FGMM) probably contribute significantly to the relative mortality in MM, as improved screening failed to influence to this day.

Our team has already demonstrated that the growth kinetics of the MM was a prognostic factor of tumor aggressiveness regardless of the thickness of the tumor. Using the same method to calculate the growth rate, an Australian team recently studied the growth rate in a population of patients suffering from MM. In this population 1/3 of MM had a growth of more than 0.5 mm per month. Clinical aspects and FGMM of these risk factors were individuals (injuries symmetrical achromic and regular occurrence among about older and low-nevi). The European and Australian people are very different in particular regarding the prevention policy, these results can not be extrapolated to the French population.The main objective is to identify risk factors for FGMM in French propulation

Enrollment

472 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient with Breslow primitive melanoma for over 1 mm skin affected

Exclusion criteria

  • Patient unable to answer questionnair concerning its melanoma history desease

Trial design

472 participants in 1 patient group

Patient with melanoma
Treatment:
Behavioral: Melanoma scale questionnair

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems